

# Godrej Consumer

BSE SENSEX

84,560

S&amp;P CNX

25,819



## Stock Info

Bloomberg	GCPL IN
Equity Shares (m)	1023
M.Cap.(INRb)/(USD\$)	1207.1 / 13.4
52-Week Range (INR)	1309 / 980
1, 6, 12 Rel. Per (%)	3/-5/2
12M Avg Val (INR M)	1670
Free float (%)	46.9

## Financials Snapshot (INR b)

Y/E Mar	2026E	2027E	2028E
Sales	157.5	176.6	194.9
Sales Gr. (%)	9.7	12.1	10.4
EBITDA	31.3	37.5	42.4
Margins (%)	19.9	21.2	21.7
Adj. PAT	21.9	27.1	31.2
Adj. EPS (INR)	21.4	26.5	30.5
EPS Gr. (%)	15.6	23.7	15.1
BV/Sh.(INR)	122.6	127.5	134.5

## Ratios

RoE (%)	17.9	21.2	23.3
RoCE (%)	15.6	19.3	21.9
Payout (%)	102.7	90.6	85.3

## Valuations

P/E (x)	54.9	44.4	38.6
P/BV (x)	9.6	9.2	8.7
EV/EBITDA (x)	39.0	32.4	28.4
Div. Yield (%)	1.9	2.0	2.2

## Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	53.1	53.1	63.0
DII	13.6	12.4	9.6
FII	18.2	19.4	22.0
Others	15.1	15.2	5.4

FII Includes depository receipts

**CMP: INR1,180**
**TP: INR1,450 (+23%)**
**Buy**

## India recovery underway; margin levers in place

We interacted with CFO of Godrej Consumer (GCPL) to understand the company's outlook on India business growth, margin recovery amid volatile raw material prices, and trends in its international business.

- GCPL's operating performance has been muted in the last few quarters owing to (1) soap value/volume contraction, (2) Underscoring performance of RCCL portfolio, (3) India gross margin contraction due to steep palm oil prices, and (4) weakness in Indonesia growth and margin. India EBITDA has contracted by more than 10% during the last four quarters, while Indonesia EBITDA has declined 10% in the last three quarters. It appears that most headwinds are unwinding and operating performance will start improving from 3QFY26 onward. Macro demand recovery is steadily improving, and GCPL has been aggressively focusing on new growth levers, distribution reach opportunities in rural markets, and TAM expansion.
- Management expects the India business to deliver high single-digit to double-digit revenue growth in 2HFY26, largely driven by volume growth. EBITDA margins are likely to recover sequentially toward the normalized 24-26% band, driven by stabilizing palm oil prices (~MYR4,100, down 15% YoY/5% QoQ), operating leverage, and cost savings (media and marketing efficiencies by 200bp up to FY28).
- Indonesia revenue fell by mid-single digits during 1HFY26; however, the recovery was swift and better than expected, with revenue likely to be flat vs. earlier guidance of possible growth pressure in 2HFY26. Indonesia may see operating margin expansion in 2HFY26. Other international geographies are sustaining earlier trends.
- We marginally increase our EPS estimates by 2% for FY27 and 1% for FY28 and expect company to deliver a CAGR of 11%/12%/18% in sales/EBITDA/adj. PAT over FY25-28. The stock currently trades at 44x FY27E EPS and 39x FY28E EPS. With the earnings outlook improving, we expect a re-rating in the valuation multiple. We reiterate our BUY rating on the stock with a TP of INR1,450 (50x Dec'27E EPS).

## India business growth outlook improves; soaps stabilizing

- GCPL's India business delivered ~4% volume growth in 1HFY26, with performance largely impacted by the soap portfolio. Excl. soaps, volume growth remained in double digits (mid-teens in 1QFY26 and double digits in 2QFY26), showing the underlying strength across other categories.
- Soaps were affected by commodity price volatility, particularly palm oil. Before the GST implementation (22<sup>nd</sup> Sep'25), GCPL undertook selective grammage reductions in the soaps portfolio to manage input cost pressure. These actions were largely limited to smaller packs (~1/3<sup>rd</sup> of soap volume), while large packs were left unchanged. The grammage actions in smaller packs impacted volume performance significantly as compared to the large packs.
- India business saw a temporary revenue impact of 3-4% in 2QFY26 owing to destocking and pricing disruptions, primarily in soaps and hair colors due to GST 2.0. Partial restocking has been placed in 3QFY26 and the remaining is expected in 4QFY26. Management expects volume growth to improve going forward, supported by lower GST rates, formalization benefits, the company's own initiatives (distribution expansion in rural, new launches, new price point introduction, etc.) and share gain opportunity from unorganized players.

**Naveen Trivedi – Research Analyst** (Naveen.Trivedi@motilaloswal.com)

**Research Analyst: Amey Tiwari** (Amey.Tiwari@motilaloswal.com) | **Tanu Jindal** (Tanu.Jindal@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

- Soap portfolio is now showing early signs of stabilization after 4-5 quarters of volatility due to RM inflation. The recent normalization in palm oil prices should support recovery, with management expecting positive value growth from 4Q onward.
- Growth momentum remains strong across other categories. In Household Insecticides, the new RNF molecule continues to drive competitive growth across formats and support market share gains. Air Fresheners sustained strong growth, with continued share gains, while the Aer Plug launch has scaled up well with healthy consumer traction and repeat purchases. Fabric Care continues to deliver strong growth, supported by market share gains in Godrej Fab.
- Management expects the India business to deliver revenue growth in high single digits to double digits in 2HFY26, with volume growth in the high single-digit to low double-digit range. EBITDA margins are likely to recover sequentially toward the normalized 24-26% band, driven by stabilizing palm oil prices (~MYR4,100, down 15% YoY/5% QoQ), operating leverage, and cost savings (media and marketing efficiencies by 200bp up to FY28).

#### **RCCL India – Underscoring performance; building blocks for stable trend**

- India RCCL business has underachieved after the acquisition, largely due to SKU rationalization and competitive challenges in the deodorants segment. GCPL has stepped up innovation-led initiatives to revive growth. Amazon Woods 4x has seen healthy repeat purchases, while KS99 continues to scale across southern markets, indicating early signs of traction. To improve penetration, the company has launched a deodorant lotion in select South Indian markets at an attractive price of INR20, including the Park Avenue deo-lotion extension in Tamil Nadu, positioned as an antiperspirant offering. The deodorants portfolio is also witnessing increasing traction in EDP formats, supported by gifting-led consumption. The condoms segment remains resilient, benefiting from a relatively stable competitive landscape dominated by a few key players. Management expects low double-digit growth in the near term, with a gradual improvement toward mid-teen growth over the medium term, while margins have stabilized and are expected to remain steady.

#### **Product innovation and expanding TAM to strengthen growth**

- GCPL continues to strengthen its growth outlook through product innovation, new category entry, and portfolio expansion. Godrej Fab and Goodnight Agarbatti have scaled up well, with GCPL emerging as the market leader in incense sticks. New launches such as Air Plug (Amazon Woods 4x), Air Pocket, and KamaSutra at INR99 have gained healthy traction across markets.
- The entry into toilet cleaners with Godrej Spic provides exposure to an ~INR30b double-digit growth category, with differentiated formulation and value pricing supporting medium-term scale-up. Moreover, the Muuchstac acquisition enables GCPL's entry into the fast-growing men's facewash segment (INR10b Indian men's facewash market), which is EPS-accretive from day one and offers multiple distribution-led growth levers.

### International business – Fast recovery for Indonesia

- Indonesia business reported a revenue decline of 5% in 1HFY26, impacted by a market slowdown and intense price competition, resulting in low single-digit volume growth. EBITDA margin contracted during 1H due to competitive pressure and weak operating leverage. Management expects a gradual recovery from 2HFY26 (better than expected), though full improvement is likely from 1QFY27 onward. EBITDA margin is expected to stabilize in 2H, with no further contraction anticipated.
- Africa (GAUM) business delivered a strong performance in 1HFY26, recording double-digit growth in revenue and profit (>25%). The growth trends are intact. Management expects mid-teen EBITDA margins to be sustainable, although currency movements and seasonality may continue to drive quarter-to-quarter volatility.
- Latin America business continues to face near-term volatility due to hyperinflation and currency depreciation, which have weighed on reported performance despite stable underlying demand.

### Valuation and view

- GCPL faced revenue growth pressure in its India business in 1HFY26 due to weak soap performance and the impact of GST transition. The growth acceleration is expected to be driven by a decline in palm oil prices, consistent strong growth for new portfolio and normalization of GST transition, which will eventually offer share gain opportunities from unorganized players.
- The company's disruptive innovations, introduction of access packs, and expansion into new growth categories will contribute to the growth trajectory. Additionally, savings in media spends of 200bp by FY28 and palm oil prices will also restore margins.
- Besides, there has been a consistent effort to fix gaps in profitability and growth in its international business.
- We expect GCPL to deliver a CAGR of 11%/12%/18% in sales/EBITDA/adj. PAT over FY25-28. The stock currently trades at 44x and 39x P/E on FY27E and FY28E, respectively. With earnings outlook improving, we expect a re-rating in the valuation multiple. We reiterate our BUY rating on the stock with a TP of INR1,450 (50x Dec'27E EPS).


**Exhibit 1: Segmental information**

Segmental Information	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Revenue (INR bn)</b>										
India	56.8	54.7	62.5	69.5	76.7	84.1	89.1	95.2	107.0	117.8
Indonesia	15.2	16.9	17.7	17.0	16.5	18.9	19.9	19.3	21.0	22.9
GAUM	24.5	23.2	25.0	30.5	34.1	31.8	26.5	32.8	37.1	41.6
Others	7.7	5.6	6.6	7.4	7.1	7.5	9.2	9.3	10.5	11.5
<b>Total</b>	<b>103.1</b>	<b>99.1</b>	<b>110.3</b>	<b>122.8</b>	<b>133.2</b>	<b>141.0</b>	<b>143.6</b>	<b>157.5</b>	<b>176.6</b>	<b>194.9</b>
<b>Revenue Gr. (%)</b>										
India	8%	-4%	14%	11%	10%	10%	6%	7%	12%	10%
Indonesia	13%	11%	4%	-4%	-3%	14%	5%	-3%	9%	9%
GAUM	12%	-5%	8%	22%	12%	-7%	-17%	24%	13%	12%
Others	-33%	-27%	19%	12%	-5%	5%	24%	1%	12%	10%
<b>Total</b>	<b>5%</b>	<b>-4%</b>	<b>11%</b>	<b>11%</b>	<b>8%</b>	<b>6%</b>	<b>2%</b>	<b>10%</b>	<b>12%</b>	<b>10%</b>
<b>Revenue Mix (%)</b>										
India	55%	55%	57%	57%	58%	60%	62%	60%	61%	60%
Indonesia	15%	17%	16%	14%	12%	13%	14%	12%	12%	12%
GAUM	24%	23%	23%	25%	26%	23%	18%	21%	21%	21%
Others	7%	6%	6%	6%	5%	5%	6%	6%	6%	6%
<b>Total</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>
<b>EBITDA (INR bn)</b>										
India	15.2	14.6	16.5	17.3	18.7	22.4	21.0	22.0	26.9	30.3
Indonesia	3.8	4.5	4.9	3.9	3.1	4.0	4.3	4.0	4.5	5.3
GAUM	2.9	2.4	2.4	3.0	3.5	3.6	4.0	4.7	5.4	6.0
Others	0.3	0.3	0.8	1.0	0.2	0.1	0.8	0.8	0.9	1.0
<b>Total</b>	<b>21.3</b>	<b>21.4</b>	<b>24.4</b>	<b>24.9</b>	<b>25.4</b>	<b>30.7</b>	<b>30.0</b>	<b>31.3</b>	<b>37.5</b>	<b>42.4</b>
<b>EBITDA margin (%)</b>										
India	26.8%	26.6%	26.5%	24.9%	24.4%	26.7%	23.6%	23.1%	25.1%	25.7%
Indonesia	25.2%	26.5%	27.6%	23.1%	18.6%	20.9%	21.4%	20.9%	21.5%	23.0%
GAUM	11.9%	10.4%	9.6%	9.7%	10.3%	11.3%	15.2%	14.2%	14.5%	14.5%
Others	3.9%	4.6%	11.8%	13.0%	3.4%	1.1%	8.7%	9.0%	9.0%	9.0%
<b>Total</b>	<b>20.7%</b>	<b>21.6%</b>	<b>22.2%</b>	<b>20.3%</b>	<b>19.1%</b>	<b>21.8%</b>	<b>20.9%</b>	<b>19.9%</b>	<b>21.2%</b>	<b>21.7%</b>
<b>EBITDA mix (%)</b>										
India	71%	68%	68%	69%	74%	73%	70%	70%	72%	71%
Indonesia	18%	21%	20%	16%	12%	13%	14%	13%	12%	12%
GAUM	14%	11%	10%	12%	14%	12%	13%	15%	14%	14%
Others	1%	1%	3%	4%	1%	0%	3%	3%	3%	2%
<b>Total</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>

Source: Company, MOFSL


## Story in charts

**Exhibit 2: Domestic volume growth expected in high single digits**




Source: Bloomberg, Company, MOFSL

**Exhibit 3: India business expected to deliver 10% revenue CAGR over FY25-28**




Source: Bloomberg, Company, MOFSL

**Exhibit 4: India gross and EBITDA margin expected to show improving trajectory**




Source: Bloomberg, Company, MOFSL

**Exhibit 5: India business expected to deliver 13% EBITDA CAGR over FY25-28**




Source: Bloomberg, Company, MOFSL

**Exhibit 6: Consolidated sales expected to post 11% CAGR over FY25-28**




Source: Bloomberg, Company, MOFSL

**Exhibit 7: Consolidated margins expected to show improvement trajectory**




Source: Bloomberg, Company, MOFSL

**Exhibit 8: Consolidated EBITDA projected to deliver 12% EBITDA CAGR over FY25-28**




Source: Bloomberg, Company, MOFSL

**Exhibit 9: Consolidated APAT projected to deliver 18% APAT CAGR over FY25-28**




Source: Bloomberg, Company, MOFSL

**Exhibit 10: GCPL – P/E (x)**



Source: Bloomberg, Company, MOFSL

**Exhibit 11: Consumer sector – P/E (x)**



Source: Bloomberg, Company, MOFSL

## Financials and valuations

Income Statement									(INR m)
Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E
<b>Net Sales</b>	<b>99,108</b>	<b>1,10,286</b>	<b>1,22,765</b>	<b>1,33,160</b>	<b>1,40,961</b>	<b>1,43,643</b>	<b>1,57,545</b>	<b>1,76,589</b>	<b>1,94,900</b>
Change (%)	-3.9	11.3	11.3	8.5	5.9	1.9	9.7	12.1	10.4
Cost of Goods Sold	42,617	49,294	60,751	67,028	63,203	65,361	74,202	81,558	88,838
<b>Gross Profit</b>	<b>56,491</b>	<b>60,992</b>	<b>62,014</b>	<b>66,132</b>	<b>77,758</b>	<b>78,282</b>	<b>83,343</b>	<b>95,031</b>	<b>1,06,062</b>
Margin (%)	57.0	55.3	50.5	49.7	55.2	54.5	52.9	53.8	54.4
Total Expenditure	77,764	86,954	97,848	1,07,768	1,10,258	1,13,612	1,26,235	1,39,088	1,52,549
<b>EBITDA</b>	<b>21,345</b>	<b>23,332</b>	<b>24,917</b>	<b>25,392</b>	<b>30,704</b>	<b>30,031</b>	<b>31,310</b>	<b>37,501</b>	<b>42,351</b>
Change (%)	1.5	9.3	6.8	1.9	20.9	-2.2	4.3	19.8	12.9
Margin (%)	21.5	21.2	20.3	19.1	21.8	20.9	19.9	21.2	21.7
Depreciation	1,973	2,039	2,099	2,363	2,410	2,340	2,524	2,592	2,706
Int. and Fin. Charges	2,174	1,266	1,102	1,757	2,964	3,501	3,147	2,468	1,586
Other Income	1,123	671	897	1,684	2,690	3,161	3,573	3,684	3,505
<b>PBT</b>	<b>18,321</b>	<b>20,698</b>	<b>22,614</b>	<b>22,955</b>	<b>28,020</b>	<b>27,351</b>	<b>29,212</b>	<b>36,124</b>	<b>41,564</b>
Change (%)	0.8	13.0	9.3	1.5	22.1	-2.4	6.8	23.7	15.1
Margin (%)	18.5	18.8	18.4	17.2	19.9	19.0	18.5	20.5	21.3
Tax	2,638	3,595	3,719	4,303	7,588	8,196	7,303	9,031	10,391
Deferred Tax									
Total tax	2,638	3,595	3,719	4,303	7,588	8,196	7,303	9,031	10,391
Tax Rate (%)	14.4	17.4	16.4	18.7	27.1	30.0	25.0	25.0	25.0
Minority interest	-8	0	-3	-4	0	0	0	0	0
<b>Adjusted PAT</b>	<b>14,725</b>	<b>17,150</b>	<b>17,936</b>	<b>17,450</b>	<b>19,787</b>	<b>18,948</b>	<b>21,909</b>	<b>27,093</b>	<b>31,173</b>
Non-rec. (Exp.)/Income	-811	-445	-98	-541	-24,769	-632	0	0	0
<b>Reported PAT</b>	<b>14,794</b>	<b>16,108</b>	<b>17,834</b>	<b>17,028</b>	<b>-5,605</b>	<b>18,522</b>	<b>21,909</b>	<b>27,093</b>	<b>31,173</b>

Balance Sheet									(INR m)
Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E
Share Capital	1,022	1,023	1,023	1,023	1,023	1,023	1,023	1,023	1,023
Reserves	77,961	93,367	1,11,302	1,36,920	1,25,097	1,19,016	1,24,370	1,29,399	1,36,562
<b>Networth</b>	<b>78,984</b>	<b>94,389</b>	<b>1,12,325</b>	<b>1,37,942</b>	<b>1,26,120</b>	<b>1,20,039</b>	<b>1,25,393</b>	<b>1,30,422</b>	<b>1,37,585</b>
Loans	26,637	17,683	16,077	10,340	31,546	38,826	24,826	16,826	8,826
Deferred Liability	-5,701	-6,378	-6,796	-6,412	-2,804	938	938	938	938
<b>Capital Employed</b>	<b>99,920</b>	<b>1,05,695</b>	<b>1,21,606</b>	<b>1,41,870</b>	<b>1,54,863</b>	<b>1,59,803</b>	<b>1,51,157</b>	<b>1,48,186</b>	<b>1,47,349</b>
Gross Block	45,229	46,302	45,888	49,936	62,817	63,709	66,709	69,709	72,709
Less: Accum. Depn.	6,308	8,553	7,463	8,822	8,785	9,262	11,786	14,378	17,084
<b>Net Fixed Assets</b>	<b>38,921</b>	<b>37,749</b>	<b>38,425</b>	<b>41,114</b>	<b>54,033</b>	<b>54,447</b>	<b>54,923</b>	<b>55,332</b>	<b>55,626</b>
Capital WIP	570	574	1,164	454	834	4,636	4,636	4,636	4,636
Goodwill	53,393	51,299	53,768	58,223	50,264	51,454	51,454	51,454	51,454
Non Curr Investments	348	194	1,711	8,393	17,875	6,279	6,779	7,279	7,779
Current Investments	6,372	6,572	8,443	21,897	17,162	31,027	25,527	21,027	16,527
<b>Currents Assets</b>	<b>43,498</b>	<b>39,672</b>	<b>47,279</b>	<b>37,880</b>	<b>40,767</b>	<b>45,131</b>	<b>44,207</b>	<b>48,902</b>	<b>55,689</b>
Inventory	17,031	17,163	21,299	15,372	12,709	14,186	21,693	24,315	26,836
Account Receivables	11,573	10,045	11,163	12,453	15,354	18,191	14,733	16,514	18,227
Cash and Bank Balance	7,702	6,722	7,843	3,907	5,469	4,831	-629	-1,004	907
Loans and Advances	259	264	1	1	0	0	0	0	0
Other Current Assets	6,934	5,479	6,974	6,147	7,235	7,923	8,410	9,077	9,719
<b>Curr. Liab. &amp; Prov.</b>	<b>43,182</b>	<b>30,366</b>	<b>29,185</b>	<b>26,091</b>	<b>26,071</b>	<b>33,172</b>	<b>36,371</b>	<b>40,445</b>	<b>44,363</b>
Account Payables	24,805	20,124	21,631	18,232	16,755	21,421	23,740	26,609	29,368
Other Liabilities	16,648	8,371	5,723	6,073	6,741	9,186	9,962	11,025	12,047
Provisions	1,729	1,871	1,832	1,786	2,576	2,565	2,669	2,811	2,948
<b>Net Current Assets</b>	<b>316</b>	<b>9,307</b>	<b>18,094</b>	<b>11,789</b>	<b>14,696</b>	<b>11,959</b>	<b>7,837</b>	<b>8,457</b>	<b>11,326</b>
<b>Net Assets</b>	<b>99,920</b>	<b>1,05,695</b>	<b>1,21,606</b>	<b>1,41,870</b>	<b>1,54,863</b>	<b>1,59,803</b>	<b>1,51,157</b>	<b>1,48,186</b>	<b>1,47,349</b>

E: MOFSL Estimates



## Financials and valuations

### Ratios

Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E
<b>Basic (INR)</b>									
<b>EPS</b>	<b>14.4</b>	<b>16.8</b>	<b>17.5</b>	<b>17.1</b>	<b>19.3</b>	<b>18.5</b>	<b>21.4</b>	<b>26.5</b>	<b>30.5</b>
Cash EPS	16.3	18.8	19.6	19.4	21.7	20.8	23.9	29.0	33.1
BV/Share	77.3	92.3	109.8	134.9	123.3	117.3	122.6	127.5	134.5
DPS	6.0	0.0	0.0	0.0	15.0	20.0	22.0	24.0	26.0
Payout (%)	41.7	0.0	0.0	0.0	77.5	108.0	102.7	90.6	85.3
<b>Valuation (x)</b>									
P/E	81.7	70.1	67.0	68.9	60.8	63.5	54.9	44.4	38.6
Cash P/E	72.0	62.7	60.0	60.7	54.2	56.5	49.2	40.5	35.5
EV/Sales	12.3	11.0	9.8	9.0	8.6	8.6	7.8	6.9	6.2
EV/EBITDA	57.2	52.0	48.5	47.3	39.4	41.0	39.0	32.4	28.4
P/BV	15.2	12.7	10.7	8.7	9.5	10.0	9.6	9.2	8.7
Dividend Yield	0.5	0.0	0.0	0.0	1.3	1.7	1.9	2.0	2.2
<b>Return Ratios (%)</b>									
RoE	19.4	19.8	17.4	13.9	15.0	15.4	17.9	21.2	23.3
RoCE (Post-tax)	17.8	17.7	17.4	15.2	15.2	13.7	15.6	19.3	21.9
RoIC	19.9	19.9	19.6	17.8	18.7	17.1	18.9	22.7	25.4
<b>Working Capital Ratios</b>									
Debtor (Days)	43	33	33	34	40	46	34	34	34
Asset Turnover (x)	2.5	2.9	3.1	3.2	2.6	2.4	2.6	2.9	3.2
<b>Leverage Ratio</b>									
Debt/Equity (x)	0.3	0.2	0.1	0.1	0.3	0.3	0.2	0.1	0.1

### Cash Flow Statement

(INR m)

Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E
Profit before Tax	18,415	20,804	21,553	21,327	1,982	26,719	29,212	36,124	41,564
Net interest	1,412	916	506	802	1,094	1,153	1,361	626	-166
Direct Taxes Paid	-3,441	-3,972	-4,475	-4,185	-3,739	-4,701	-7,303	-9,031	-10,391
(Inc)/Dec in WC	-2,613	-452	-5,362	933	-4,559	351	-1,337	-996	-957
Others	2,109	3,001	2,284	2,629	25,921	2,245	2,524	2,592	2,706
<b>CF from Operations</b>	<b>15,881</b>	<b>20,296</b>	<b>14,506</b>	<b>21,507</b>	<b>20,699</b>	<b>25,767</b>	<b>24,456</b>	<b>29,316</b>	<b>32,755</b>
Inc in FA	-1,520	-1,639	-2,765	-2,197	-2,766	-5,592	-3,000	-3,000	-3,000
<b>Free Cash Flow</b>	<b>14,361</b>	<b>18,658</b>	<b>11,741</b>	<b>19,309</b>	<b>17,933</b>	<b>20,175</b>	<b>21,456</b>	<b>26,316</b>	<b>29,755</b>
Pur of Investments	-1,305	-289	-4,744	-16,377	-6,130	477	5,000	4,000	4,000
Others	-1,348	-1,186	-2,081	1,075	-24,305	524	7,737	4,329	4,340
<b>CF from Investments</b>	<b>-4,173</b>	<b>-3,114</b>	<b>-9,589</b>	<b>-17,499</b>	<b>-33,201</b>	<b>-4,591</b>	<b>9,737</b>	<b>5,329</b>	<b>5,340</b>
Inc in Debt	-1,280	-16,194	-2,198	-6,344	22,652	7,318	-14,000	-8,000	-8,000
Dividend Paid	-9,859	0	0	0	-5,114	-25,573	-22,506	-24,552	-26,598
Interest Paid	-1,519	-1,589	-1,123	-1,116	-2,620	-3,111	-3,147	-2,468	-1,586
<b>CF from Fin. Activity</b>	<b>-12,953</b>	<b>-18,162</b>	<b>-3,795</b>	<b>-7,943</b>	<b>14,064</b>	<b>-21,815</b>	<b>-39,653</b>	<b>-35,020</b>	<b>-36,184</b>
<b>Inc/Dec of Cash</b>	<b>-1,246</b>	<b>-980</b>	<b>1,121</b>	<b>-3,936</b>	<b>1,562</b>	<b>-639</b>	<b>-5,460</b>	<b>-375</b>	<b>1,911</b>
Add: Beginning Balance	8,947	7,702	6,722	7,843	3,907	5,469	4,831	-629	-1,004
<b>Closing Balance</b>	<b>7,702</b>	<b>6,722</b>	<b>7,843</b>	<b>3,907</b>	<b>5,469</b>	<b>4,831</b>	<b>-629</b>	<b>-1,004</b>	<b>907</b>

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.



Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/Publish/ViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh

Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: No.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors  
Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,  
Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.